ArticleJournal of extracellular vesicles2026
Nanomotor-Driven Extracellular Vesicles With Effective Tissue Penetration for Targeted Therapy of Primary Ovarian Insufficiency.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Stem cells and their derived extracellular vesicles (EVs) offer hope for functional reconstruction and fertility in premature ovarian insufficiency (POI) caused by gonadotoxic drugs. However, the clinical application of EVs is impeded by their instability, limited tissue penetration, and lack of targeted delivery to ovarian injury sites. Here, we introduce an injectable hydrogel loaded with nanomotor-driven EVs (LEVs-Gel) for targeted POI therapy. In the POI ovarian microenvironment, reactive oxygen species (ROS) and inducible nitric oxide synthase (iNOS) are highly expressed, acting as chemoattractants to promote the chemotactic behavior of nanomotors LEVs. The LEVs are loaded in a thermosensitive hydrogel to enhance the retention and stability of EVs at the ovary. Following local injection of LEVs-Gel into the ovaries of POI mice, the nanomotors LEVs effectively penetrated the epithelial layer and the tunica albuginea, significantly enhancing the permeability of the cortical and medullary regions. This intervention successfully restored ovarian endocrine and reserve functions, thereby improving reproductive fertility. Further mechanistic studies revealed that the therapeutic efficacy of LEVs-Gel is mediated through the maintenance of oxidative-antioxidative balance, inhibition of apoptosis, and promotion of ovarian angiogenesis. Overall, this integrated therapy presents a promising targeted strategy for patients with POI caused by chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.